Kidney Care Innovation: Medtech’s Next Frontier or Overhyped Trend?
The recent declaration by a medtech venture capital firm that kidney care is entering a new era of innovation is both timely and expected, but it warrants a critical lens.…
JPM26 Deal Activity Disappoints, But Signals Deeper Industry Shifts in Pharma and Medtech
The tepid dealmaking observed at JPM26 should not be mistaken for stagnation in the healthcare sector. Instead, it highlights a deeper recalibration as pharmaceutical companies brace for the impending patent…
EMA-EUCOPE Meeting: A Missed Opportunity for Meaningful Industry-Regulator Dialogue
The announcement of the fourth bilateral meeting between the European Medicines Agency (EMA) and the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) might seem routine, but it underscores a persistent challenge…
Fresenius CEO’s Call for a Healthcare ‘Fundamental Rethink’ Masks Deeper Industry Failures
Fresenius CEO’s remarks at Davos26 about the need for a “fundamental rethink” in healthcare delivery are less a visionary call to action and more a glaring indictment of how stagnant…
EMA’s Veterinary Medicines Info Day 2026: A Missed Opportunity for Industry Innovation and Engagement
The European Medicines Agency’s decision to host the Veterinary Medicines Info Day in a purely online format reflects both the evolving digital landscape and a cautious approach to stakeholder engagement.…
Passwordless Authentication: Healthcare IT’s Top Priority That Remains Elusive
The recent survey by Imprivata highlighting the enthusiasm among healthcare IT leaders for passwordless authentication is both unsurprising and deeply telling. It underscores a growing awareness that traditional password-based security…
EMA’s 2026 Product Management Service Day: A Missed Opportunity for Deeper Industry Engagement
The European Medicines Agency’s decision to host the Product Management Service (PMS) information day as a half-day online broadcast is emblematic of the ongoing tension between accessibility and depth in…
PathoCare’s $1.75 Billion Valuation Signals Shifting Dynamics in Medical Diagnostics Investment
PathoCare Holdings’ recent announcement of a $1.75 billion valuation via a private third-party tender offer is more than just a financial milestone—it’s a clear indicator of evolving investor confidence in…
2025’s Medtech Shakeup Sets the Stage for a Turbulent 2026
The medical device industry is at a pivotal crossroads as we look toward 2026, and the seismic shifts in 2025 are more than just fleeting headlines—they are harbingers of a…
Neurable’s $35M Raise Signals a Critical Inflection Point for Brain-Computer Interface Commercialization
Neurable’s recent $35 million Series A funding round is more than just a financial milestone—it represents a pivotal moment for the brain-computer interface (BCI) sector, especially as it inches closer…